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Background
We have developed a novel, acutely replicating VEE-SHIV
chimeric particle (RCP) as a vaccine against HIV that com-
bines the superior and long-lived immunity of a live-
attenuated virus with the safety of non-replicating partic-
ulate antigens. These chimeric particles contain a replicat-
ing VEE-SHIV genome and are capable of infecting
susceptible cells bearing hCD4/hCCR5, undergoing cyto-
plasmic replication, genomic RNA encapsidation, assem-
bly and particle release. Due to the replicative nature of
the RCPs, lentiviral proteins will be expressed for an
extended period of time in vaccinated individuals thus
inducing a more comprehensive immune response com-
pared to nonreplicating antigens but without the safety
issues associated with integrating, live-attenuated lentivi-
ruses.
Methods
VEE-SHIV RCP vaccines contain the VEE UTRs along with
nonstructural genes required for RNA replication. Struc-
tural genes of VEE, which are under the control of the VEE
subgenomic 26S promoter, were replaced with SIV gag +/
- an attenuated protease (PR, A28S). The VEE capsid frag-
ment (aa75-132), predicted to bind VEE genomic RNA,
was incorporated by replacing the NC region of gag while
maintaining the proteolytic cleavage sites. HIV Env was
added downstream from a second VEE subgenomic pro-
moter.
Results
VEE-SHIV RCP vaccines were evaluated for particle forma-
tion, encapsidation of genomic RNA and infectivity in
both primate and rodent. Inclusion of the VEE C fragment
and attenuated protease in the VEE-SHIV RCP increased
the specific infectivity by two logs. In addition, these chi-
meric particles replicated for more than 35 passages in
both rodent and primate cell lines. At the conclusion of
the viral passage experiment, the total viral titer increased
1-2 logs compared with the non-passaged virus.
Conclusion
The novel replicative nature of these chimeric particles
should lead to enhanced immunogenicity and will be
investigated in hCD4/hCCR5 transgenic mice as well as
non-human primates.
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